WP
LRMR icon

Woodline Partners’s Larimar Therapeutics LRMR Stock Holding History

Woodline Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.27M Hold
1,400,850
– – 0.01% 727
2026
Q1 		$6.3M Buy
1,400,850
+600,000
+75% +$2.4M 0.02% 615
2025
Q4 		$3.05M Sell
800,850
-822,000
-51% -$3.2M 0.01% 715
2025
Q3 		$5.24M Buy
1,622,850
+1,000,168
+161% +$3.75M 0.02% 557
2025
Q2 		$1.8M Hold
622,682
– – 0.01% 737
2025
Q1 		$1.34M Hold
622,682
– – 0.01% 728
2024
Q4 		$2.41M Sell
622,682
-621,869
-50% -$4.11M 0.02% 624
2024
Q3 		$8.15M Buy
1,244,551
+1,966
+0.2% +$15.8K 0.07% 331
2024
Q2 		$9.01M Buy
1,242,585
+92,252
+8% +$707K 0.09% 262
2024
Q1 		$8.73M Buy
1,150,333
+354,107
+44% +$2.76M 0.08% 289
2023
Q4 		$3.62M Buy
796,226
+86,545
+12% +$292K 0.04% 344
2023
Q3 		$2.8M Sell
709,681
-972,232
-58% -$3.68M 0.03% 370
2023
Q2 		$5.26M Hold
1,681,913
– – 0.06% 280
2023
Q1 		$7.62M Sell
1,681,913
-259,826
-13% -$1.36M 0.1% 237
2022
Q4 		$8.02M Hold
1,941,739
– – 0.11% 245
2022
Q3 		$6.21M Buy
+1,941,739
New +$4.86M 0.09% 260

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Woodline Partners's LRMR Position: Q2 2026 in Review

Woodline Partners held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 1,400,850 shares worth $4.27M. The position accounts for 0.01% of the portfolio, ranked #727.

Woodline Partners first reported a position in LRMR in Q3 2022 and has held it in 16 quarters since. The position peaked at $9.01M in Q2 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Woodline Partners held 1,400,850 shares of Larimar Therapeutics worth $4.27M as of Q2 2026.
  • Woodline Partners left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #727 holding.
  • Woodline Partners first reported a position in Larimar Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Woodline Partners's Larimar Therapeutics position peaked at $9.01M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.